HER2外显子20插入突变中AYVM向AYMM转变诱导NSCLC对酪氨酸激酶抑制剂耐药
对40例HER2突变NSCLC患者基线与耐药后配对样本行基因组测序,未发现主导性继发HER2突变,但12例(38.7%)出现继发HER2突变,其中HER2 p.E770_A771insAYMM可降低鼠源HER2突变肺腺癌细胞系对吡咯替尼的敏感性。药物筛选显示莫博赛替尼与达克替尼可有效抑制携带该突变的肿瘤生长。
要点
- 耐药后未发现主导性继发HER2突变,12例(38.7%)继发HER2突变中仅2个驱动HER2自磷酸化。
- HER2 p.E770_A771insAYMM突变降低鼠源HER2突变肺腺癌细胞系对吡咯替尼的敏感性。
- 莫博赛替尼与达克替尼可有效抑制携带HER2 p.E770_A771insAYMM突变的肿瘤生长。
核心结论
- 本研究揭示一种新的耐药形式,即继发突变叠加于原发突变之上,并为克服吡咯替尼耐药提供潜在序贯策略的见解。
研究设计与样本
- 对40例患者的基线与耐药后配对样本行基因组测序以识别耐药相关突变。
- 采用整合计算与实验方法在体外和体内验证耐药机制并探索克服耐药的策略。
主要发现
- 耐药后分析未识别任何主导性继发HER2突变。
- 12个继发HER2突变(38.7%)发生于HER2 p.Y772_P775dup突变基础上,其中单核苷酸变异占75%、插入缺失占25%。
- 体外实验中仅两个突变导致Ba/F3细胞HER2自磷酸化和IL3非依赖性增殖,提示其余10个继发突变为 passenger 突变。
- 体内外验证显示HER2 p.E770_A771insAYMM突变降低鼠源HER2突变肺腺癌细胞系对吡咯替尼的敏感性,并无效抑制HER2及其下游通路。
- 药物筛选表明莫博赛替尼和达克替尼可有效抑制携带HER2 p.E770_A771insAYMM突变的肿瘤生长。
关键数值与推荐
- 12个继发HER2突变(38.7%)中单核苷酸变异占75%、插入缺失占25%。
- 体外实验中仅两个突变导致Ba/F3细胞HER2自磷酸化和IL3非依赖性增殖。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pyrotinib, a novel pan-HER tyrosine kinase inhibitor, has demonstrated substantial anti-tumor activity in patients with NSCLC harboring HER2 mutations. Nevertheless, the inevitable resistance to pyrotinib necessitates an in-depth understanding of the underlying mechanisms. METHODS: Resistance-associated mutations were identified through genomic sequencing of paired baseline and post-resistance samples from 40 patients. Integrated computational and experimental approach were utilized to validate the resistance mechanisms and explore strategies for overcoming resistance in vitro and in vivo. RESULTS: Analysis of novel mutations upon the development of resistance did not identify any predominant secondary HER2 mutations. Nevertheless, 12 secondary HER2 mutations (38.7%) occurred either as single nucleotide variations (75%) or insertions-deletions (25%), on the basis of HER2 p.Y772_P775dup mutation. Only two mutations led to HER2 autophosphorylation and IL3-independent proliferation of Ba/F3 cells from the in vitro experiments, implying that the remaining 10 secondary mutations were passenger mutations. Further in vivo and in vitro validation showed that the HER2 p.E770_A771insAYMM mutation diminished the sensitivity of murine HER2 mutant lung adenocarcinoma cell line to pyrotinib, with ineffective inhibition of HER2 and its downstream pathways. Drug screening indicated that mobocertinib and dacomitinib could effectively restrain the growth of tumors bearing the HER2 p.E770_A771insAYMM mutation. CONCLUSIONS: Our findings unveil a new form of resistance-a secondary mutation superimposed on the original mutation-and offer insights into a potentially sequential strategy for overcoming resistance to pyrotinib.
引用
- Mao S, Liu X, Wang L, et al. AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC. J Thorac Oncol. 2024. PMID: 39725168. doi:10.1016/j.jtho.2024.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。